We are pleased to announce the appointment of the new ICN Chairperson, Thomas Hiemstra, and Vice Chair-person, Henry Yau.
Dr Thomas Hiemstra is senior trialist with the Cambridge Clinical Trials Unit and Lecturer in Trials with the University of Cambridge. He is a consultant nephrologist and leads a portfolio of National and International trials in nephrology. He chairs the UK Renal Trials Network and co-chairs the International Society of Nephrology Action on Clinical Trials initiative. Dr Hiemstra has a particular interest in Public and Patient Involvement in trials, and has served as Director of the Patient Led Research Hub since 2015.
Mr. Yau is the Managing Director of The University of Hong Kong Clinical Trials Centre (HKU-CTC). He holds a B.Sc. in Biochemistry and a MBA in Finance. Mr. Yau has deep-seated knowledge and experience in clinical trials and the pharmaceutical industry since early 1990s, and now undertakes multiple roles in many clinical research related bodies such as Advisor (Asia) of the Training and Resources in Research Ethics Evaluation Program (TRREE), Committee of Management Member of The University of Hong Kong-Shenzhen Hospital Clinical Trials Centre (HKU-SZH CTC), Executive Director of the Committee of Ethics Review of the World Federation of Chinese Medicine Societies (WFCMS), Expert Advisor on Biomedical Innovation and Development of Shenzhen Pingshan District of China, and Advisory Board Member of China Medical University Hospital Clinical Trial Center of Taiwan (CMUH-CTC).”
We look forward to their contributions to ICN and the development of the institution under their guidance!
For more information visit: ICN-Connect
Published December 23, 2019
Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.
Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…
An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.